Proof-of-concept phase II trial of R 118 in patients with intermittent claudication
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2014
Price : $35 *
At a glance
- Drugs R 118 (Primary)
- Indications Intermittent claudication
- Focus Proof of concept; Therapeutic Use
- 13 Aug 2014 Rigel Pharmaceuticals has discontinued the R 118 programme due to the side-effect profile in phase I trials, according to a media release.
- 13 Aug 2014 Status changed from planning to withdrawn prior to enrolment, according to a Rigel Pharmaceuticals media release.
- 13 Mar 2014 New trial record